Back to results
US 9,358,282 B2Granted
Re-directed immunotherapy
AssigneeThe University of Birmingham
InventorsMark Cobbold, David Millar
Life of this patent
Estimating the term…
Abstract
The invention provides an agent for preventing or treating a condition characterized by the presence of unwanted cells, the agent comprising: (i) a targeting moiety that is capable of targeting to the unwanted cells; and (ii) a T cell antigen, wherein the T cell antigen can be released from the targeting moiety by selective cleavage of a cleavage site in the agent in the vicinity of the unwanted cells.
Claims26
An agent for retargeting T cells to cancer cells, the agent comprising:
- (i) a targeting moiety that is capable of targeting to the cancer cells, wherein the targeting moiety is Rituximab or Cetuximab;
- (ii) a T cell epitope capable of eliciting a T cell response in a subject, wherein the T cell epitope is NLVPMVATV (SEQ ID NO:
- 21), and
- (iii) a peptide linker comprising a peptide cleavage site cleavable by a tumor associated protease and
- wherein the linker can be selectively cleaved by the tumor associated protease to release the T cell epitope in the vicinity of, and outside of, the cancer cell.
2 more elements
Dependencies are inferred from the claim text.